Theoretically, blocking EMT signalling is a promising anti‐tumour strategy that “kills many birds with one stone.” The current clinical drugs are typically designed to block a single EMT signal pathway, such as lapatinib targeting EGFR and alectinib targeting ALK. This evidence concerns the gene ALK and neoplasm.